Establishment and characterization of NCC-SS5-C1: a novel patient-derived cell line of synovial sarcoma
- 2 June 2022
- journal article
- research article
- Published by Springer Nature in Human Cell
- Vol. 35 (4) , 1290-1297
Abstract
Synovial sarcoma (SS) is a rare and aggressive mesenchymal malignancy driven by a unique chromosomal translocation that generates the expression of the SS18:SSX fusion protein. It occurs at almost any anatomical site and most commonly in young adults. The standard curative treatment for primary SS is a wide surgical resection combined with radiotherapy and/or neoadjuvant chemotherapy. The prognosis of SS varies among patients, with the 5 years survival rate ranging from 50 to 60% in adults and 90% in children. Although patient-derived cell lines are a useful resource for the development of new therapies, only a few are available from public cell banks. Therefore, this study aimed to establish and characterize a novel SS cell line. We successfully established a novel cell line, NCC-SS5-C1, harboring an SS18-SSX1 fusion gene. NCC-SS5-C1 cells demonstrated constant growth and invasion ability. We performed integrative drug screening using eight SS cell lines, including NCC-SS5-C1 cells, and examined the response spectrum of existing anticancer agents. We conclude that NCC-SS5-C1 is a useful resource for studying SS.Keywords
Funding Information
- AMED (20ck0106537h0002)
This publication has 34 references indexed in Scilit:
- Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)Annals of Oncology, 2014
- Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paperAnnals of Oncology, 2014
- Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysisJournal of Surgical Oncology, 2014
- Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial SarcomaCell, 2013
- Synovial Sarcoma Is a Stem Cell MalignancyStem Cells, 2010
- Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005Cancer, 2009
- Synovial sarcomaCancer, 2009
- A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for PatientsClinical Cancer Research, 2008
- Long-Term Outcomes for Synovial Sarcoma Treated With Conservation Surgery and RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Histologic Grade, But Not SYT-SSX Fusion Type, Is an Important Prognostic Factor in Patients With Synovial Sarcoma: A Multicenter, Retrospective AnalysisJournal of Clinical Oncology, 2004